Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0AUJJN
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
WO2024140927A1-ADC-G (DAR2)
|
|||||
| Synonyms |
WO2024140927A1-ADC-G (DAR2)
Click to Show/Hide
|
|||||
| Organization |
WUXI BIOLOGICS (SHANGHAI) CO., LTD.
|
|||||
| Drug Status |
Investigative
|
|||||
| Drug-to-Antibody Ratio |
2
|
|||||
| Structure |
|
|||||
| Antibody Name |
mAb-D
|
Antibody Info | ||||
| Antigen Name |
Vascular endothelial growth factor A (VEGFA)
|
Antigen Info | ||||
| Payload Name |
Doxorubicin
|
Payload Info | ||||
| Therapeutic Target |
DNA topoisomerase 2-alpha (TOP2A)
|
Target Info | ||||
| Linker Name |
Succinimidyl-4- (N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC)
|
Linker Info | ||||
| Conjugate Type |
Random conjugation through reduced inter-chain cysteines.
|
|||||
| Combination Type |
Doxoiubicin-SMCC
|
|||||